Tirzepatide
SURMOUNT-3
Eli Lilly · Phase 3 · Completed · Enrollment 579
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide | 94.37% | 88.03% | 73.94% | 54.93% |
| Placebo | 10.65% | 4.81% | 2.06% | 1.03% |
Not shown
Every selected arm is drawn.